Hepatocellular adenoma (patient information)
For the WikiDoc page on this topic, click here
Hepatocellular adenoma |
Hepatocellular adenoma On the Web |
---|
Risk calculators and risk factors for Hepatocellular adenoma |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2]
Overview
What are the symptoms of Hepatocellular adenoma?
Small hepatocellular adenomas are generally asymptomatic.[1][2][3]
- Abdominal pain is the most common presenting symptom in some patients, and the pain is usually related to tumoral hemorrhage.
- Right upper quadrant abdominal fullness or discomfort is present in 40% of cases due to mass effect.
- Eventually, spontaneous rupture or hemorrhage may occur, leading to acute abdominal pain with progression to hypotension and even death.
- Patients with hepatocellular adenomas typically have a history of oral contraceptive use (females) and long term anabolic steroids use (males).[4][5]
What causes Hepatocellular adenoma?
- The causes of hepatocellular adenoma include;[6][7][8][9][10][11][12][13][14]
- Oral contraceptive medications
- The causal relationship is proportional to the hormonal dose and duration of medication, highest in women over 30 years of age and after 24 months of using oral contraceptives.
- Pregnancy
- Glycogen storage disease types I,II and IV
- Long term use of anabolic androgenic steroids
- Metabolic syndrome
- Maturity onset diabetes of young (MODY)
- Obesity
- Clomiphene
- Familial adenomatous polyposis
- Vascular disorders such as portal vein agenesis, Budd-Chiari syndrome and hereditary hemorrhagic telangiectasia.
- Oral contraceptive medications
Who is at highest risk?
- The most important risk factor in the development of hepatocellular adenoma is use of oral contraceptive medications.[15]
- Drospirenone and Ethinyl estradiol
- Norethindrone acetate and Ethinyl estradiol
- Norgestimate and Ethinyl estradiol
- Norgestrel and Ethinyl estradiol
- The risk is proportional to:[4]
- Hormonal dose
- Duration of medication
- Other risk factors include:[4][16][17][18]
Risk factors for malignant transformation
The risk factor for malignant transformation of hepatic adenoma to hepatocellular carcinoma is:[19]
- Gender (men)
- Size (> 8 cm)
- Subtype (beta-catenin-activated HCA)
Diagnosis
When to seek urgent medical care?
Treatment options
Medical Therapy
There is no specific medical therapy for the hepatocellular adenoma.[1][2] Historically, hepatocellular adenomas were treated with a wait and watch policy, with surgical intervention recommended for larger (>5cm) tumors. In asymptomatic female patients suffering from hepatocellular adenomas, the first step is to stop the offending drug (such as OCPs) and check adenoma size on follow-up. The wait and watch policy is recommended when hepatocellular adenomas are <5cm or regress (to <5cm) following cessation of offending drug (OCPs) and no further growth is detected.[3] An annual follow-up with MRI or ultrasound is scheduled for patients untill menopause.[4][5][6][7][8][9][10]
Surgical Therapy
Where to find medical care for Hepatocellular adenoma?
Directions to Hospitals Treating Hepatocellular adenoma
Prevention of Hepatocellular adenoma
What to expect (Outlook/Prognosis)?
Possible complications
Source
- ↑ Agrawal, Shefali; Agarwal, Sheela; Arnason, Thomas; Saini, Sanjay; Belghiti, Jacques (2015). "Management of Hepatocellular Adenoma: Recent Advances". Clinical Gastroenterology and Hepatology. 13 (7): 1221–1230. doi:10.1016/j.cgh.2014.05.023. ISSN 1542-3565.
- ↑ Massimo Roncalli, Amedeo Sciarra & Luca Di Tommaso (2016). "Benign hepatocellular nodules of healthy liver: focal nodular hyperplasia and hepatocellular adenoma". Clinical and molecular hepatology. 22 (2): 199–211. doi:10.3350/cmh.2016.0101. PMID 27189732. Unknown parameter
|month=
ignored (help) - ↑ David Q. Wang, Laurie M. Fiske, Caroline T. Carreras & David A. Weinstein (2011). "Natural history of hepatocellular adenoma formation in glycogen storage disease type I". The Journal of pediatrics. 159 (3): 442–446. doi:10.1016/j.jpeds.2011.02.031. PMID 21481415. Unknown parameter
|month=
ignored (help) - ↑ 4.0 4.1 4.2 Barthelmes L, Tait IS (2005). "Liver cell adenoma and liver cell adenomatosis". HPB (Oxford). 7 (3): 186–96. doi:10.1080/13651820510028954. PMC 2023950. PMID 18333188.
- ↑ Introduction. Hindawi(2015). http://www.hindawi.com/journals/ijh/2013/374170. Accessed on November 2, 2015
- ↑ M. Kawakatsu, V. Vilgrain, S. Erlinger & H. Nahum (1997). "Disappearance of liver cell adenoma: CT and MR imaging". Abdominal imaging. 22 (3): 274–276. PMID 9107649. Unknown parameter
|month=
ignored (help) - ↑ W. H. Marks, N. Thompson & H. Appleman (1988). "Failure of hepatic adenomas (HCA) to regress after discontinuance of oral contraceptives. An association with focal nodular hyperplasia (FNH) and uterine leiomyoma". Annals of surgery. 208 (2): 190–195. PMID 2840865. Unknown parameter
|month=
ignored (help)</ref<ref>H. Tesluk & J. Lawrie (1981). "Hepatocellular adenoma. Its transformation to carcinoma in a user of oral contraceptives". Archives of pathology & laboratory medicine. 105 (6): 296–299. PMID 6263214. Unknown parameter|month=
ignored (help) - ↑ D. Carrasco, M. Barrachina, M. Prieto & J. Berenguer (1984). "Clomiphene citrate and liver-cell adenoma". The New England journal of medicine. 310 (17): 1120–1121. doi:10.1056/NEJM198404263101716. PMID 6323982. Unknown parameter
|month=
ignored (help) - ↑ G. B. Coombes, J. Reiser, F. J. Paradinas & I. Burn (1978). "An androgen-associated hepatic adenoma in a trans-sexual". The British journal of surgery. 65 (12): 869–870. PMID 737424. Unknown parameter
|month=
ignored (help) - ↑ U. Beuers, W. O. Richter, M. M. Ritter, B. Wiebecke & P. Schwandt (1991). "Klinefelter's syndrome and liver adenoma". Journal of clinical gastroenterology. 13 (2): 214–216. PMID 1851773. Unknown parameter
|month=
ignored (help) - ↑ N. S. Alshak, J. Cocjin, L. Podesta, R. van de Velde, L. Makowka, P. Rosenthal & S. A. Geller (1994). "Hepatocellular adenoma in glycogen storage disease type IV". Archives of pathology & laboratory medicine. 118 (1): 88–91. PMID 8285839. Unknown parameter
|month=
ignored (help) - ↑ P. Labrune, P. Trioche, I. Duvaltier, P. Chevalier & M. Odievre (1997). "Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature". Journal of pediatric gastroenterology and nutrition. 24 (3): 276–279. PMID 9138172. Unknown parameter
|month=
ignored (help) - ↑ S. Bala, P. H. Wunsch & W. G. Ballhausen (1997). "Childhood hepatocellular adenoma in familial adenomatous polyposis: mutations in adenomatous polyposis coli gene and p53". Gastroenterology. 112 (3): 919–922. PMID 9041254. Unknown parameter
|month=
ignored (help) - ↑ J. K. Baum, J. J. Bookstein, F. Holtz & E. W. Klein (1973). "Possible association between benign hepatomas and oral contraceptives". Lancet (London, England). 2 (7835): 926–929. PMID 4126557. Unknown parameter
|month=
ignored (help) - ↑ L. Rosenberg (1991). "The risk of liver neoplasia in relation to combined oral contraceptive use". Contraception. 43 (6): 643–652. PMID 1651205. Unknown parameter
|month=
ignored (help) - ↑ U. Beuers, W. O. Richter, M. M. Ritter, B. Wiebecke & P. Schwandt (1991). "Klinefelter's syndrome and liver adenoma". Journal of clinical gastroenterology. 13 (2): 214–216. PMID 1851773. Unknown parameter
|month=
ignored (help) - ↑ N. S. Alshak, J. Cocjin, L. Podesta, R. van de Velde, L. Makowka, P. Rosenthal & S. A. Geller (1994). "Hepatocellular adenoma in glycogen storage disease type IV". Archives of pathology & laboratory medicine. 118 (1): 88–91. PMID 8285839. Unknown parameter
|month=
ignored (help) - ↑ S. Bala, P. H. Wunsch & W. G. Ballhausen (1997). "Childhood hepatocellular adenoma in familial adenomatous polyposis: mutations in adenomatous polyposis coli gene and p53". Gastroenterology. 112 (3): 919–922. PMID 9041254. Unknown parameter
|month=
ignored (help) - ↑ Aamann L, Schultz N, Fallentin E, Hamilton-Dutoit S, Vogel I, Grønbæk H (2015). "[Hepatocellular adenoma - new classification and recommendations]". Ugeskr Laeger. 177 (12). PMID 25786843.